Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II study.
Thaler J, Hilbe W, Apfelbeck U, Linkesch W, Sill H, Seewann H, Pont J, Bernhart M, Stöger M, Niessner H, Abbrederis K, Geissler D, Hausmaninger H, Lin W, Ludwig H, Lang A, Duba C, Fluckinger T, Greil R, Grünewald K, Konwalinka G, Niederwieser D, Fridrik M. Thaler J, et al. Among authors: seewann h. Leuk Res. 1997 Jan;21(1):75-80. doi: 10.1016/s0145-2126(96)00084-7. Leuk Res. 1997. PMID: 9029189 Clinical Trial.
Treatment of chronic myelogenous leukemia with interferon alfa-2c: response rate and toxicity in a phase II multicenter study. The Austrian Biological Response Modifier (BRM) Study Group.
Thaler J, Gastl G, Fluckinger T, Niederwieser D, Huber H, Seewann H, Silly H, Lang A, Abbrederis C, Gadner H, et al. Thaler J, et al. Among authors: seewann h. Semin Hematol. 1993 Jul;30(3 Suppl 3):17-9. Semin Hematol. 1993. PMID: 8235697 Clinical Trial. No abstract available.
Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long-term results of a multicenter phase-II study. Austrian Biological Response Modifier (BRM) Study Group.
Thaler J, Gastl G, Fluckinger T, Niederwieser D, Huber H, Seewann H, Sill H, Lang A, Falk M, Duba C, Utermann G, Kühr T, Aulitzky W, Huber C. Thaler J, et al. Among authors: seewann h. Ann Hematol. 1996 Jun;72(6):349-55. doi: 10.1007/s002770050185. Ann Hematol. 1996. PMID: 8767103 Clinical Trial.
Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-C.
Hilbe W, Kühr T, Apfelbeck U, Fridrik M, Seewann H, Stöger M, Linkesch W, Pont J, Baldinger C, Hartner E, Bernhart M, Geissler D, Krieger O, Lang A, Lin W, Ludwig H, Duba C, Greil R, Gast G, Thaler J. Hilbe W, et al. Among authors: seewann h. Leuk Lymphoma. 2001 Nov-Dec;42(6):1283-8. doi: 10.3109/10428190109097753. Leuk Lymphoma. 2001. PMID: 11911409 Clinical Trial.
A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML).
Kühr T, Burgstaller S, Apfelbeck U, Linkesch W, Seewann H, Fridrik M, Michlmayr G, Krieger O, Lutz D, Lin W, Pont J, Köck L, Abbrederis K, Baldinger C, Buder R, Geissler D, Hausmaninger H, Lang A, Zabernigg A, Duba C, Hilbe W, Eisterer W, Fiegl M, Greil R, Gastl G, Thaler J; Austrian CML Study Group. Kühr T, et al. Among authors: seewann h. Leuk Res. 2003 May;27(5):405-11. doi: 10.1016/s0145-2126(02)00223-0. Leuk Res. 2003. PMID: 12620292 Clinical Trial.
CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.
Fridrik MA, Hausmaninger H, Linkesch W, Stöger M, Sill H, Neubauer M, Seewann HL, Klocker J, Haidinger R, Schiller L, Pont J, Raudaschl G, Falk M, Radaszkiewicz T. Fridrik MA, et al. Among authors: seewann hl. J Clin Oncol. 1996 Jan;14(1):227-32. doi: 10.1200/JCO.1996.14.1.227. J Clin Oncol. 1996. PMID: 8558202 Clinical Trial.
Efficacy and toxicity of 2-Chlorodeoxyadenosine (Cladribine)--2 h infusion for 5 days--as first-line treatment for advanced low grade non-Hodgkin's lymphoma.
Fridrik MA, Jäger G, Kienzer HR, Hausmaninger H, Oppitz P, Krieger O, Zabernigg A, Lang A, Neubauer M, Weidinger G, Schiller L, Seewann HL, Chott A, Linkesch W. Fridrik MA, et al. Among authors: seewann hl. Eur J Cancer. 1998 Sep;34(10):1560-4. doi: 10.1016/s0959-8049(98)00140-3. Eur J Cancer. 1998. PMID: 9893628 Clinical Trial.
47 results